Urinary biomarkers in bladder cancer

where do we stand?

Abhishek Bhat, Chad Ritch

Research output: Contribution to journalArticle

Abstract

PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.

Original languageEnglish (US)
Pages (from-to)203-209
Number of pages7
JournalCurrent opinion in urology
Volume29
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Urinary Bladder Neoplasms
Biomarkers
Cell Biology
Costs and Cost Analysis
Sensitivity and Specificity
Cystoscopy
Metabolomics
Fluorescence In Situ Hybridization
Epigenomics
Urine
Population

ASJC Scopus subject areas

  • Urology

Cite this

Urinary biomarkers in bladder cancer : where do we stand? / Bhat, Abhishek; Ritch, Chad.

In: Current opinion in urology, Vol. 29, No. 3, 01.05.2019, p. 203-209.

Research output: Contribution to journalArticle

@article{981831e6f259408893ac4cb9b82cb7db,
title = "Urinary biomarkers in bladder cancer: where do we stand?",
abstract = "PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.",
author = "Abhishek Bhat and Chad Ritch",
year = "2019",
month = "5",
day = "1",
doi = "10.1097/MOU.0000000000000605",
language = "English (US)",
volume = "29",
pages = "203--209",
journal = "Current Opinion in Urology",
issn = "0963-0643",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Urinary biomarkers in bladder cancer

T2 - where do we stand?

AU - Bhat, Abhishek

AU - Ritch, Chad

PY - 2019/5/1

Y1 - 2019/5/1

N2 - PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.

AB - PURPOSE OF REVIEW: To provide a current comprehensive review of the available urinary biomarkers for the detection and surveillance of bladder cancer. RECENT FINDINGS: The limitations of urine cytology and invasive nature of cystoscopic evaluation have led to a growing search for an ideal, cost-effective biomarker with acceptable sensitivity and specificity. Current FDA approved biomarkers such as UroVysion fluorescent in situ hybridization, Immunocyt, and nuclear matrix protein 22 do not have the specificity, and thus positive predictive value to warrant their cost as a routine adjunct or replacement for cystoscopy. Several promising commercially available assays such as Cxbladder, Assure MDx, and Xpert BC may perform better than cytology in select populations. Novel genomic, epigenetic, inflammatory, and metabolomic-based assays are being analyzed as potential urinary biomarkers. SUMMARY: Urinary biomarkers with high sensitivity and specificity are an unmet need in bladder cancer. Several new assays may meet these criteria and future research may justify use in clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85064322920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064322920&partnerID=8YFLogxK

U2 - 10.1097/MOU.0000000000000605

DO - 10.1097/MOU.0000000000000605

M3 - Article

VL - 29

SP - 203

EP - 209

JO - Current Opinion in Urology

JF - Current Opinion in Urology

SN - 0963-0643

IS - 3

ER -